SUMMARY Background
Directly acting antiviral agents (DAA) have been associated with hepatic decompensation, especially in patients with pre-treatment cirrhosis, but this risk is not well defined.
Aim
To determine the incidence of hepatic decompensation, liver transplantation, death and worsening renal function in patients treated with a Paritaprevir/ritonavir, Ombitasvir, Dasabuvir (PrOD), sofosbuvir/simeprevir or sofosbuvir/ledipasvir regimen.
Methods
We followed ERCHIVES participants treated with the above regimens for up to 12 weeks post-treatment. We excluded those with HIV, HBsAg+ and pre-existing diagnosis of hepatic decompensation and hepatocellular carcinoma.
Results
Of 3728 persons on PrOD, 1578 on sofosbuvir/simeprevir and 10 440 on sofosbuvir/ ledipasvir, incidence rates (95% CI) of hepatic decompensation/1000 patient-years were 10.6 (5.89-17.36) for the PrOD, 32.4 (20.74-48.16 ) for the sofosbuvir/simeprevir and 13.0 (9.74-17.10) for the sofosbuvir/ledipasvir. Among those with baseline cirrhosis, these rates were 36.9 (19.1-64.5), 61.8 (38.2-94.5) and 41.1 (29.9-55.2) respectively, while among those without cirrhosis at baseline, these rates were 2.7 (0.6-8.0), 7.5 (1.5-21.8) and 2.7 (1.2-5.4). Advanced fibrosis was associated with increased risk of hepatic decompensation in all groups [HR (95% CI) per 0.5 unit increase in FIB-4 score: PrOD 1.11 (1.07-1.16); sofosbuvir/simeprevir 1.03 (1.01-1.05); sofosbuvir/ledipasvir 1.02 (1.01-1.03)]. There were no deaths. Proportion of persons with eGFR decrease >30 ml/min/1.73 m 2 was higher among the PrOD group, but presence of cirrhosis did not appear to affect this.
INTRODUCTION
In December 2014, the Food and Drug Administration (FDA) approved a combination consisting of paritaprevir/ritonavir ombitasvir co-packaged with dasabuvir tablets (PrOD or Viekira Pak; AbbVie Inc., North Chicago, IL, USA) for treatment of hepatitis C virus (HCV) genotype 1 infected patients, including those with cirrhosis. 1 In October 2015, FDA updated its guidance regarding the safety of PrOD regimen and ombitasvir, paritaprevir and ritonavir regimen (Technivie), based on 26 worldwide cases of worsening liver injury, hepatic decompensation and liver failure. The guidance was focused on patients with pre-treatment advanced liver disease, specifically those with moderate to severe hepatic impairment (Child-Pugh B and C). 2 In most cases, liver injury occurred within 1-4 weeks of starting treatment with these drugs, and in some cases, these drugs were started in patients with contraindications to these drugs.
Other isolated reports suggest the possibility that another protease inhibitor containing regimen might also be associated with hepatic decompensation during or following drug exposure. 3 Sofosbuvir-based regimens have also been associated with isolated cases of hepatotoxicity, lactic acidosis and bradyarrythmias, though the latter may have been caused by a drug interaction with amiodarone. [4] [5] [6] [7] It is not known what proportion of severe adverse events to new drugs, including those mentioned above, are reported to the FDA. It is possible that some cases go unreported. It is also not known if reporting is selective to certain drugs in a class. Larger post-marketing surveillance studies, especially comparing various agents and regimens in similar therapeutic categories are crucial to better understand and characterise such risk. This is especially true for uncommon events, for which true risk is difficult to estimate from case reports or registration trials. To better understand the incidence and risk of hepatic decompensation in patients treated with newer directing acting antiviral agents (DAA), we analysed all persons treated with the PrOD, sofosbuvir/simeprevir and sofosbuvir/ledipasvir regimens in the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES). Based on other anecdotal, unsubstantiated reports of risk of certain DAAs upon progression of chronic kidney disease (CKD) (informal personal communication with several HCV treatment providers) our secondary aim was to determine the number of patients who developed worsening of renal function on or after treatment with the new DAA regimens.
METHODS

Data sources and study participants
We used ERCHIVES to identify HCV infected patients within the Department of Veterans Affairs (VA) healthcare system who were initiated on PrOD, sofosbuvir/ simeprevir or sofosbuvir/ledipasvir regimens. ERCHIVES is a well-established cohort of HCV infected Veterans and demographically matched HCV uninfected controls, assembled using multiple national VA databases. [8] [9] [10] [11] [12] [13] [14] [15] [16] Treatment initiation was defined as receiving >14 days of one of the study regimens. We excluded those with HIV coinfection, hepatitis B surface antigen positivity, hepatocellular carcinoma diagnosed any time before baseline, any diagnosis of hepatic decompensation prior to baseline, those in whom baseline FIB-4 score was not available and those who did not have any follow-up after treatment initiation.
Definitions
Cirrhosis was defined using the FIB-4 score, as used in our previous publications from ERCHIVES. 16, 17 FIB-4 score was calculated using the following formula:
Average of two values closest to baseline was used to calculate the FIB-4 score to account for a temporary elevation of laboratory values. A cut-off of 3.5 was used to define presence of cirrhosis at baseline. 16 We also assessed severity of liver disease using the Model for End-stage Liver Disease (MELD) score, which was calculated using the formula:
MELD ¼ 3:8 Ã log e ðserum bilirubin½mg/dLÞ þ 11:2 Ã log e ðINRÞ þ 9:6
Ã log e ðserum creatinine½mg/dLÞ þ 6:4
Diabetes was defined by presence of any of the following criteria: (i) Glucose >200 mg/dL on two separate occasions; (ii) ICD-9 codes (two or more outpatient OR one or more in-patient) PLUS treatment with an oral hypoglycaemic or insulin for >30 days; (iii) ICD-9 codes (two out-patient OR one in-patient) PLUS glucose >126 mg/dL on two separate occasions; (iv) Glucose >200 mg/dL on one occasion PLUS treatment with an oral hypoglycaemic or insulin for >30 days. 18 Chronic kidney disease was defined by estimating glomerular filtration rate using the CKD-EPI equation. 9 Alcohol and drug abuse and dependence were defined by presence of at least one in-patient or two out-patient ICD-9CM (International Classification of Diseases, 9th edition, Clinical Modification) codes. For diabetes, alcohol and drug abuse and dependence variables, ICD-10 codes were used for data after 1 October 2015.
Main outcome
Our main outcome of interest was hepatic decompensation, defined as a primary hospital discharge diagnosis or two or more out-patient diagnoses for ascites, spontaneous bacterial peritonitis, or oesophageal variceal haemorrhage. This definition has been validated against chart reviews and has been used in previous published studies. 19 Time at risk was defined as time from treatment initiation to 12 weeks after completion of a prescribed course of treatment. We used the 12 weeks post-treatment completion since ICD-9 based diagnostic coding may be delayed till visits after the actual diagnosis date.
Our secondary outcome was worsening of renal function, defined as a decline in estimated glomerular filtration rate of >30 mL/min/1.73 m 2 from baseline. Since changes in renal function may progress very slowly, the time at risk was calculated from baseline to the last observation date in ERCHIVES. We also determined the number of persons who died or underwent a liver transplant in the same time frame.
Statistical analyses
Baseline characteristics of the persons on each regimen were compared using the chi-squared test or t-test, as appropriate for normally distributed variables and Kruskal-Wallis test for non-normally distributed variables. We compared the incidence of hepatic decompensation per 1000 patient-years, for the three DAA regimens. We also determined the number and rate of liver transplantation and deaths on each of the regimens. We compared the number of persons who had worsening renal function on each of the regimens. We generated Kaplan-Meier curves to demonstrate time to first hepatic decompensation event and worsening renal function by treatment regimen, stratified by presence of cirrhosis at baseline. Multivariable Cox regression analysis was used to determine factors associated with hepatic decompensation and worsening renal function. We used SAS (version 9.4; SAS Institute Inc., Cary, NC, USA) and STATA version 11 (Stata Corp., College Station, TX, USA) for analyses.
Regulatory approvals
The study was approved by the Institutional Review Board at VA Pittsburgh Healthcare System, Pittsburgh, PA. Appropriate approvals were also obtained from each of the databases from where data were retrieved.
RESULTS
Our final evaluable dataset consisted of 3728 persons in the PrOD group, 1578 in the sofosbuvir/simeprevir group and 10 440 in the sofosbuvir/ledipasvir group ( Figure 1 ). Baseline characteristics of the three groups are provided in Table 1 (Table 2) . Substituting MELD score instead of cirrhosis produced hepatic decompensation incidence rates which were two to four times higher among those with MELD score of >9 compared with those who had scores of ≤9, a trend similar to that seen with using cirrhosis as a marker of severity of liver disease. There were no deaths in any group while on treatment and for the 12-week period after completion of treatment. Number of persons with worsening renal function in the PrOD group was 45 [rate (95% CI)/1000 patient-years: 31.5 (23.0-42.1)], three in the sofosbuvir/ simeprevir [rate (95% CI)/1000 patient-years: 4.0 (0.83-11.7)] and 41 in the sofosbuvir/ledipasvir group [rate (95% CI)/1000 patient-years: 10.25 (7.4-13.9)] ( Table 2) . Figure 2 shows Kaplan-Meier curves depicting hepatic decompensation free survival among various treatment groups. There was no statistically significant difference between the three treatment regimens in persons with or without cirrhosis (Figure 2a,b) . Persons on PrOD regimen were more likely to have worsening of renal function compared with other regimens (P < 0.05; Figure 2c,d) .
In multivariable Cox regression analysis, increasing severity of liver disease as measured by FIB-4 score was associated with a higher risk of hepatic decompensation events in all treatment groups. The hazards ratios (HR) and 95% confidence intervals for each 0.5 unit increase in FIB-4 score were as follows: 1.11 (1.07-1.16) for PrOD; 1.03 (1.01-1.05) for sofosbuvir/simeprevir; 1.02 (1.01-1.03) for sofosbuvir/ledipasvir (Table 3) . No other factor was consistently associated with such risk in all treatment groups.
Supplementary analyses
We also determined the incidence rates of HD, liver transplantation and worsening renal function by individual lab values (serum albumin, bilirubin, INR and platelet counts) to further understand and identify patients at highest risk. These results are presented in Table S1a-d. We repeated Cox multivariable regression analysis using cirrhosis as a categorical variable (Table S2) , and MELD score as a continuous variable (Table S3) , which showed similar trends to the original results.
To compare PrOD regimen with sofosbuvir/simeprevir and sofosbuvir/ledipasvir regimens, we also constructed Kaplan-Meier curves depicting hepatic decompensation free survival among PrOD regimen with and without cirrhosis vs. the other regimens with and without cirrhosis. There was no difference in hepatic decompensation events among PrOD vs. other treatment groups stratified by presence of cirrhosis at baseline (Figure S2a-d) . Similar analyses for worsening of renal function are provided in Figure S2 , but show a small, but statistically significant difference between PrOD vs. sofosbuvir/ledipasvir without cirrhosis and PrOD vs. sofosbuvir/simeprevir with cirrhosis.
Since the FDA communication noted that most hepatic decompensation events occurred within 1-4 weeks of starting treatment with PrOD, 2 we conducted additional analysis limiting the time at risk from treatment initiation to end of treatment. These results were similar to those reported above, although number of events was smaller.
DISCUSSION
To our knowledge, this is the first large study specifically looking at the incidence of hepatic decompensation and worsening renal function in patients treated with newer DAA agents. We found the overall incidence of these events to be low, but there was a strong association of hepatic decompensation events with presence of increasingly severe liver disease at time of treatment initiation. The event rate for hepatic decompensation was higher in those treated with sofosbuvir/simeprevir regimen, but was generally similar for PrOD and sofosbuvir/ledipasvir regimens. PrOD regimen was initially approved for HCV genotype 1 infected patients with or without cirrhosis. 1 The sustained virological response rates were reported to be over 90% in both groups. 20, 21 In multiple clinical trials, there was no significant signal suggesting a particularly increased risk of liver failure in patients with preexisting cirrhosis. [20] [21] [22] [23] [24] [25] [26] [27] Based on post-marketing surveillance reports, the FDA added warnings to the prescribing information making severe hepatic impairment a contraindication to treatment with PrOD. A Medline search using "Viekira" or any of the components, plus "liver failure", "hepatic decompensation" or "hepatic impairment" did not yield any studies reporting cases of hepatic decompensation (search performed on 7 March 2016). Hence, the true incidence and risk of such events with the newer DAA has not been previously delineated. Paritaprevir and dasabuvir area under the concentration-time curve (AUC) are significantly higher in patients with severe hepatic impairment. Difference in dasabuvir AUC between healthy controls and those with mild to moderate hepatic impairment were less than 35%. However, the difference was 62% for paritaprevir. 28 Sofosbuvir and ledipasvir concentrations are not significantly affected in patients with severe hepatic impairment. 29 Simeprevir concentrations have not been well studied in patients with moderate to severe hepatic impairment, but higher exposures have been reported in patients with severe hepatic impairment. 30 These limited pharmacokinetic data, combined with higher risk of hepatic decompensation events in our study in the sofosbuvir/simeprevir group may suggest a class-risk with HCV protease inhibitors. However, this needs to be studied in more details before such class-risk can be confirmed.
Initiated on treatment
There are no data about the effect of newer DAAs upon the risk of renal disease. Patients with HCV infection are at risk for progressive and advanced CKD, which may be due to HCV infection itself or due to the differential prevalence of the traditional risk factors for CKD in this population. 9, 14, 31 Overall numbers of persons who developed worsening renal function was quite low, and no signal associating it with presence of cirrhosis was detected. Sofosbuvir/simeprevir regimen was associated with small but statistically significant increase in risk of CKD progression as shown in the Kaplan-Meier curves, the reason for which is unclear and needs further study. The follow-up time for this outcome was from treatment initiation to the last encounter recorded in the ERCHIVES database. This provides reasonable assurance that progression of CKD is not a major concern with these regimens with our current state of knowledge. There are certain limitations to our study which provide a context for appropriate interpretation of our results. We analysed an existing database in a real-world setting, and not in a randomised clinical trial setting. Diagnosis of cirrhosis was based on a non-invasive marker (FIB-4), which was obtained during routine clinical care. Hepatic decompensation events were diagnosed based on ICD-9 codes, although we have validated these codes in a prior study. 19 Comparison of various study regimens in real-world settings requires caution, since there is a possibility of a selection bias, an indicationbias (different indications for different regimens), or treatment-preference bias (some providers preferring one treatment over another). There is an inherent risk of hepatic decompensation in HCV infected with cirrhosis even without any treatment-associated exacerbation of liver injury. Approximately, 10% of HCV infected persons develop hepatic decompensation within 9 years of being diagnosed. 16 Our study does not compare the treated persons with untreated controls to determine the risk attributable to treatment itself. In conclusion, the overall incidence of hepatic decompensation and worsening renal function with PrOD and sofosbuvir/ledipasvir regimens is low, and predominantly in the subpopulation with pre-treatment cirrhosis. Incidence of hepatic decompensation is higher among those treated with sofosbuvir/simeprevir regimen. Incidence of worsening renal function is similarly higher in those with pre-existing cirrhosis, and higher in those treated with the PrOD regimen. Long-term follow-up is needed to determine long-term safety of these regimens.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article: Table S1 . Albumin (1a), bilirubin (1b), INR (1c) and platelets (1d) added to the Cox multivariable regression analysis model. Table S2 . Factors associated with hepatic decompensation in patients treated with various regimens (Using cirrhosis as a categorical variable). Table S3 . Factors associated with hepatic decompensation in patients treated with various regimens (using MELD score as a continuous variable instead of FIB-4). Table S4 . Albumin, Platelets and Bilirubin with hepatic decompensation in patients treated with various regimens. Figure S1 . Kaplan-Meier curves demonstrating hepatic decompensation free survival, by treatment group and presence of cirrhosis at baseline. Figure S2 . Kaplan-Meier curves demonstrating development of progressive renal disease, by treatment group and presence of cirrhosis at baseline.
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